Top

Published in:

01-05-2009 | Biological Child and Adolescent Psychiatry - Original Article

Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?

Authors: Sheila P. Garcia, Julia Guimarães, Juliana F. Zampieri, Ana Luiza Martinez, Guilherme Polanczyk, Luis Augusto Rohde

Published in: Journal of Neural Transmission | Issue 5/2009

Abstract

There are controversial evidence in the literature on the role of comorbid anxiety disorders (ANX) in the improvement of attention-deficit/hyperactivity disorder (ADHD) symptoms with methylphenidate (MPH) treatment. Our main objective was to assess differences in the response to MPH treatment in children and adolescents with ADHD with and without comorbid ANX. We extensively evaluated response to MPH in a naturalistic study of 280 children and adolescent with ADHD according to DSM-IV criteria. Psychiatric diagnoses (ADHD, ANX, and other comorbidities) were assessed by semi-structured interviews (K-SADS-E). Response to MPH was assessed by means of total score in the Swanson, Nolan, and Pelham Scale-version IV (SNAP-IV) after 1 month of treatment. There was no significant between-group difference in the response to treatment with MPH after 1 month either when SNAP-IV scores were assessed dimensionally or categorically (moderate response) (P > 0.05). Our findings suggest that comorbid ANX do not interfere in the response to MPH on core ADHD symptoms.

Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, Riddle M, Oatis M, Greenhill L, Skrobala A, March J, Gammon P, Robinson J, Lazell R, McMahon DJ, Ritz L, RUPP ADHD/Anxiety Study Group (2005) Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry 44(5):418–427PubMedCrossRef

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. Author, Washington

Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366(9481):237–248PubMedCrossRef

Biederman J, Newcorn J, Sprich S (1991) Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:565–577

Cohen J (1998) Statistical power analysis for the behavioral sciences. Erlbaum Associates, Hillsdale

Correia Filho AG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA (2005) Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry 44:748–755PubMedCrossRef

Diamond IR, Tannock R, Schachar RJ (1999) Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 38(4):402–409PubMedCrossRef

Goez H, Back-Bennet O, Zelnik N (2007) Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder. J Child Neurol 22(5):538–542PubMedCrossRef

Holcman MM (2006) Avaliação do efeito das perdas de seguimento nas análises feitas pelo estimador produto-limite de Kaplan-Meier e pelo modelo de riscos proporcionais de Cox. Doctoral Thesis, Faculdade de Saúde Pública da USP, São Paulo

Jensen PS, Martin D, Cantwell DP (1997) Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry 36(8):1065–1079PubMedCrossRef

Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B (2001) ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40:147–158PubMedCrossRef

Mattos P, Serra-Pinheiro MA, Rohde LA, Pinto D (2006) A Brazilian version of the MTA-SNAP-IV for evaluation of symptoms of attention-deficit/hyperactivity disorder and oppositional-defiant disorder. Rev Psiquiatr RS 28(3):290–297

Mercadante MT, Asbahr F, Rosário-Campos MC, Ayres AM, Ferrari MC, Assumpção FB, Miguel EC (1995) K-SADS—entrevista semi-estruturada para diagnóstico em psiquiatria da infância, versão epidemiológica. PROTOC Hospital das Clínicas da FMUSP, São Paulo

National Institutes of Health (2000) National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 39:182–193CrossRef

Orvaschel H (1985) Psychiatric interviews suitable for use in research with children and adolescents. Psychopharmacol Bull 21:737–744PubMed

Polanczyk GV, Eizirik M, Aranovich V, Denardin D, Silva TL, Conceição TV, Pianca TG, Rohde LA (2003) Interrater agreement for the schedule for affective disorders and schizophrenia epidemiological version for school-age children (K-SADS-E). Rev Bras Psiquiatr 25:87–90PubMedCrossRef

Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948PubMedCrossRef

Reinhardt MC, Benetti L, Victor MM, Grevet EH, Belmonte-de-Abreu P, Faraone SV, Rohde LA (2007) Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/hyperactivity disorder? J Clin Psychiatry 68:1109–1116PubMedCrossRef

Rohde LA (2002) ADHD in Brazil: the DSM-IV criteria in a culturally different population. J Am Acad Child Adolesc Psychiatry 41:1131–1133PubMedCrossRef

Rohde LA (2008) Is there a need to reformulate attention deficit hyperactivity disorder criteria in future nosologic classifications? Child Adolesc Psychiatr Clin N Am 17(2):405–420PubMedCrossRef

Rohde LA, Biederman J, Busnello ED, Zimmermann H, Schmitz M, Martins S, Tramontina S (1999) ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions and impairments. J Am Acad Child Adolesc Psychiatry 6:716–722

Rohde LA, Szobot C, Polanczyk G, Schmitz M, Martins S, Tramontina S (2005) Attention-deficit/hyperactivity disorder in a diverse culture: do research and clinical findings support the notion of a cultural construct for the disorder? Biol Psychiatry 57(11):1436–1441PubMedCrossRef

Souza I, Pinheiro MA, Denardin D, Mattos P, Rohde LA (2004) Attention-deficit/hyperactivity disorder and comorbidity in Brazil: comparisons between two referred samples. Eur Child Adolesc Psychiatry 13(4):243–248PubMedCrossRef

Spencer T, Biederman J, Wilens T, Harding M, O’Donnel D, Griffin S (1996) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409–432PubMedCrossRef

Stevens J, Quittner AL, Abikoff H (1998) Factors influencing elementary school teachers’ ratings of ADHD and ODD behaviors. J Clin Child Psychol 27:406–414PubMedCrossRef

Tannock R (2000) Attention-deficit/hyperactivity disorders with anxiety disorders. In: Brown T (ed) Attention-deficit disorders and comorbidities in children, adolescents, and adults. American Psychiatric Press, Washington, pp 125–170

Tannock R, Ickowicz A, Schachar R (1995) Differential effect of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 34:886–896PubMedCrossRef

The MTA Cooperative Group (1999) Multimodal Treatment Study of Children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56(12):1073–1086CrossRef

Victor MM, Grevet EH, Salgado CAI, Kalil KLS, Sousa NO, Karam RG, Rohde LA, Belmonte-de-Abreu P, Bau CHD (2009) Exploring reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder (submitted)

Wechsler D (1991) Manual for the Wechsler intelligence scale for children, 3rd edn. The Psychological Corporation, San Antonio

Title: Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?
Authors: Sheila P. Garcia
Julia Guimarães
Juliana F. Zampieri
Ana Luiza Martinez
Guilherme Polanczyk
Luis Augusto Rohde
Publication date: 01-05-2009
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 5/2009
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-009-0211-3

At a glance: The STEP trials

Springer Medicine

Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Evidence of angiogenic vessels in Alzheimer’s disease

Differentiating attention-deficit/hyperactivity disorder inattentive and combined types: a 1H-magnetic resonance spectroscopy study of fronto-striato-thalamic regions

Nitric oxide- and cGMP-active compounds affect the discharge of substantia nigra pars reticulata neurons: in vivo evidences in the rat

N-methyl-d-aspartate 2b receptor subtype (NR2B) promoter methylation in patients during alcohol withdrawal

Genetic variation of serotonin receptor function affects prepulse inhibition of the startle

Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity